BACKGROUND: A role of blood coagulation in the pathogenesis of peripheral arterial disease (PAD) and Buerger's disease, or thromboangiitis obliterans (TAO), remains unclear. OBJECTIVE: To test the hypothesis that PAD and TAO are associated with prothrombotic phenotype of a fibrin clot. PATIENTS AND METHODS: Ex vivo plasma fibrin clot permeability, turbidimetry and efficiency of fibrinolysis were investigated in 106 patients with PAD and 20 patients with TAO and compared with the respective control groups matched for age, sex, and cardiovascular risk factors. The progression of PAD and TAO were evaluated during follow-up of 3-7.5 years. PAD patients were characterized by lower clot permeability (-18.8%, p=0.005), shorter lag phase (-35.3%, p<0.001), higher maximum clot absorbancy (+22.4%, p<0.001), prolonged clot lysis time (+30.6%, p=0.003), and lower rate of D-dimer release from clots in the presence of recombinant tissue plasminogen activator (-16.5%, p=0.009), but twofold lower maximum D-dimer levels released from clots during lysis (p<0.001) than the controls. Similar, but more pronounced abnormalities were observed in TAO patients versus controls (all p<0.01). Seventeen PAD (16%) and 3 (15%) TAO patients were lost to follow-up. The progression observed in 47 (52.8%) PAD patients and 10 (59%) TAO patients was associated with lower clot permeability (-14.6%, p=0.009, and -17.5%, p=0.02) and prolonged clot lysis (+11.3%, p=0.004, and +12.4%, p=0.03, respectively). CONCLUSIONS: Unfavorably altered fibrin clot properties are observed in both PAD and TAO. Denser fibrin clots with reduced susceptibility to lysis might characterize the progression of both diseases during long-term follow-up.
BACKGROUND: A role of blood coagulation in the pathogenesis of peripheral arterial disease (PAD) and Buerger's disease, or thromboangiitis obliterans (TAO), remains unclear. OBJECTIVE: To test the hypothesis that PAD and TAO are associated with prothrombotic phenotype of a fibrin clot. PATIENTS AND METHODS: Ex vivo plasma fibrin clot permeability, turbidimetry and efficiency of fibrinolysis were investigated in 106 patients with PAD and 20 patients with TAO and compared with the respective control groups matched for age, sex, and cardiovascular risk factors. The progression of PAD and TAO were evaluated during follow-up of 3-7.5 years. PAD patients were characterized by lower clot permeability (-18.8%, p=0.005), shorter lag phase (-35.3%, p<0.001), higher maximum clot absorbancy (+22.4%, p<0.001), prolonged clot lysis time (+30.6%, p=0.003), and lower rate of D-dimer release from clots in the presence of recombinant tissue plasminogen activator (-16.5%, p=0.009), but twofold lower maximum D-dimer levels released from clots during lysis (p<0.001) than the controls. Similar, but more pronounced abnormalities were observed in TAO patients versus controls (all p<0.01). Seventeen PAD (16%) and 3 (15%) TAO patients were lost to follow-up. The progression observed in 47 (52.8%) PAD patients and 10 (59%) TAO patients was associated with lower clot permeability (-14.6%, p=0.009, and -17.5%, p=0.02) and prolonged clot lysis (+11.3%, p=0.004, and +12.4%, p=0.03, respectively). CONCLUSIONS: Unfavorably altered fibrin clot properties are observed in both PAD and TAO. Denser fibrin clots with reduced susceptibility to lysis might characterize the progression of both diseases during long-term follow-up.
Authors: Xueming Wu; Niranjan Balu; Wen Li; Yong Chen; Xiaoyue Shi; China M Kummitha; Xin Yu; Chun Yuan; Zheng-Rong Lu Journal: Am J Nucl Med Mol Imaging Date: 2013-09-19
Authors: Karin Mauer; Andrew W Gardner; Tarun W Dasari; Julie A Stoner; Steve M Blevins; Polly S Montgomery; Jorge F Saucedo; J Emilio Exaire Journal: Angiology Date: 2014-04-27 Impact factor: 3.619
Authors: Florian Posch; Stefanie Hofer; Johannes Thaler; Lena Hell; Oliver Königsbrügge; Ella Grilz; Lisa-Marie Mauracher; Johanna Gebhart; Christine Marosi; Bernd Jilma; Ingrid Pabinger; Cihan Ay Journal: Transl Res Date: 2019-08-29 Impact factor: 7.012
Authors: Marie-Claire F Kleinegris; Joke Konings; Jan W Daemen; Yvonne Henskens; Bas de Laat; Henri M H Spronk; Arina J Ten Cate-Hoek; Hugo Ten Cate Journal: Front Cardiovasc Med Date: 2017-04-20
Authors: Claire S Whyte; Irina N Chernysh; Marco M Domingues; Simon Connell; John W Weisel; Robert A S Ariens; Nicola J Mutch Journal: Thromb Haemost Date: 2016-08-25 Impact factor: 5.249